Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

TandemAI Raises $35 Million for AI/WetLab Drug Discovery Operations

publication date: Mar 2, 2023

Suzhou TandemAI, a drug discovery company, closed a $35 million Series A round to expand its platform that integrates breakthrough computational tools with wet lab biophysics, medicinal chemistry and biology. Established in 2021, TandemAI was formed with the goal of lowering the barrier to entry for drug discovery’s most advanced tools, including physics-based molecular simulation, AI and access to high performance computing infrastructure. The company completed a $25 million Seed and pre-Series A financing in late 2021. Qiming Venture Partners led the financing along with participation from OrbiMed, Eight Roads Ventures and F Prime Capital. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital